Biotech Asset Analysis Platform

MBRS Bio Terminal is a biotech asset analysis platform that evaluates drug development risk using biological signals. It provides a biology-first framework for assessing drug assets across indications.

Traditional biotech asset analysis often relies on market signals, precedent transactions, and clinical narratives. MBRS introduces a complementary analytical layer focused on underlying biology.

The platform is designed to help users assess:

• Clinical failure probability
• Biological alignment between asset and indication
• Relative differentiation across therapeutic approaches

By quantifying biological risk and differentiation, MBRS provides an additional layer of analysis that can be used alongside existing diligence frameworks.